What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy

M Hickey; KM Moss; EO Krejany; CD Wrede; A Brand; J Kirk; HL Symecko; SM Domchek; T Tejada-Berges; A Trainer; GD Mishra

Journal article

What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy

M Hickey, KM Moss, EO Krejany, CD Wrede, A Brand, J Kirk, HL Symecko, SM Domchek, T Tejada-Berges, A Trainer, GD Mishra

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2021

DOI: 10.1016/j.ygyno.2021.07.029

Abstract

Objective: To measure menopausal symptoms and quality of life up to 12 months after risk-reducing salpingo-oophorectomy (RRSO) and to measure the effects of hormone therapy. Methods: Prospective observational study of 95 premenopausal women planning RRSO and a comparison group of 99 who retained their ovaries. Vasomotor symptoms and menopausal-related quality of life (QoL) were measured by the Menopause-Specific QoL Intervention scale at baseline, 3, 6 and 12 months. Chi-square tests measured differences in prevalence of vasomotor symptoms between RRSO vs the comparison group and by hormone therapy use. Change in QoL were examined with multilevel modelling. Results: Three months after RRSO h..

View full abstract

University of Melbourne Researchers

Martha Hickey Author

Alison Trainer Author

Related Projects (2)

PROMOTING AND ADVANCING MIDLIFE HEALTH IN WOMEN

Australia has an ageing population and women spend around one third of their lives after menopause. Optimising physical and emotional health..

IMPACT OF RISK-REDUCING BILATERAL SALPINGO-OOPHORECTOMY ON NON-CANCER OUTCOMES IN YOUNG HIGH-RISK WOMEN: A MULTICENTRE PROSPECTIVE STUDY

Growing numbers of Australian women are being identified at increased inherited risk of ovarian cancer. Removing the ovaries and Fallopian t..

Grants

Awarded by Royal Melbourne Hospital

Funding Acknowledgements

This study was supported by Register4 through its members' participation in research and/or provision of samples and information (register4.org.au). In Australia this study was supported by public funding provided by the National Health and Medical Research Council of Australia (NHMRC; Grant #APP1048023), and by philanthropic funding provided by The Royal Women's Hospital (Melbourne, Australia), The Women's Foundation (Melbourne, Australia), Australia New Zealand Gynaecological Oncology Group (ANZGOG, Sydney, Australia) and the Westmead Hospital Familial Cancer Service (Sydney, Australia). In the USA this study was supported by philanthropic funding provided by the Basser Centre for BRCA and the Susan G. Komen organization (Grant #SAC150003). None of the funding agencies had a role in the design or conduct of the study, nor the collection, management, analyses or interpretation of the data, nor the preparation or approval of this manuscript. MH is supported by a NHMRC Practitioner Fellowship (ID #1058935). SMD is supported by the Komen Foundation for the Cure. GDM is supported by a NHMRC Principal Research Fellowship (ID #APP1121844).